Evidence map›Paper›PMID 33122906›Full record

ArticleInternational journal of nanomedicine2020

Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy.

Buyankhishig Dorjsuren, Birendra Chaurasiya, Zixuan Ye, Yanyan Liu, Wei Li, Chaoyang Wang, Di Shi, Colin E Evans, Thomas J Webster, Yan Shen

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. PeerJ · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Buyankhishig Dorjsuren *Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Birendra Chaurasiya *Department of Pediatrics, Critical Care Division, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0001-7243-1625
Zixuan YeDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Yanyan LiuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Wei LiDepartment of Cardiology, Affiliated Hospital of Yangzhou University, Yangzhou 225002, People's Republic of China.
Chaoyang WangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Di ShiDepartment of Chemical Engineering, Northeastern University, Boston, MA, USA.ORCID 0000-0002-4894-732X
Colin E EvansDepartment of Pediatrics, Critical Care Division, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0002-9251-357X
Thomas J WebsterDepartment of Chemical Engineering, Northeastern University, Boston, MA, USA.ORCID 0000-0002-2028-5969
Yan ShenDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
China Pharmaceutical University · CNNortheastern University · USNorthwestern University · USYangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne major limitation of cancer chemotherapy is a failure to specifically target a tumor, potentially leading to side effects such as systemic cytotoxicity. In this case, we have generated a cancer cell-targeting nanoparticle-liposome drug delivery system that can be activated by near-infrared laser light to enable local photo-thermal therapy and the release of chemotherapeutic agents, which could achieve combined therapeutic efficiency.

methodsTo exploit the magnetic potential of iron oxide, we prepared and characterized citric acid-coated iron oxide magnetic nanoparticles (CMNPs) and encapsulated them into thermo-sensitive liposomes (TSLs). The chemotherapeutic drug, doxorubicin (DOX), was then loaded into the CMNP-TSLs, which were coated with an antibody against the epidermal growth factor receptor (EGFR), cetuximab (CET), to target EGFR-expressing breast cancer cells in vitro and in vivo studies in mouse model.

resultsThe resulting CET-DOX-CMNP-TSLs were stable with an average diameter of approximately 120 nm. First, the uptake of TSLs into breast cancer cells increased by the addition of the CET coating. Next, the viability of breast cancer cells treated with CET-CMNP-TSLs and CET-DOX-CMNP-TSLs was reduced by the addition of photo-thermal therapy using near-infrared (NIR) laser irradiation. What is more, the viability of breast cancer cells treated with CMNP-TSLs plus NIR was reduced by the addition of DOX to the CMNP-TSLs. Finally, photo-thermal therapy studies on tumor-bearing mice subjected to NIR laser irradiation showed that treatment with CMNP-TSLs or CET-CMNP-TSLs led to an increase in tumor surface temperature to 44.7°C and 48.7°C, respectively, compared with saline-treated mice body temperature ie, 35.2°C. Further, the hemolysis study shows that these nanocarriers are safe for systemic delivery.

conclusionOur studies revealed that a combined therapy of photo-thermal therapy and targeted chemotherapy in thermo-sensitive nano-carriers represents a promising therapeutic strategy against breast cancer.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell Line, TumorCetuximabDoxorubicinDrug Delivery SystemsErbB ReceptorsFemaleFerric CompoundsHumansHyperthermia, InducedLiposomesMagnetite NanoparticlesMice, Inbred BALB CPhotothermal TherapyCetuximabDoxorubicinEGFR protein, humanErbB ReceptorsFerric Compoundsferric oxideLiposomesMagnetite Nanoparticlesbreast cancercetuximabcombined therapydoxorubicinepidermal growth factor receptorsiron oxide magnetic nanoparticles

Identifiers

PMID33122906
PMCPMC7591010
OpenAlexW3093950500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.